• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/12/25 7:05:30 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    8-K
    0001703647falseNASDAQ00017036472025-08-122025-08-12

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 12, 2025

     

    Korro Bio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-39062

    47-2324450

    (State or other jurisdiction of

    incorporation)

    (Commission

    File Number)

    (IRS Employer
    Identification No.)

    60 First Street, 2nd floor, Suite 250

    Cambridge, MA

     

    02141

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: (617) 468-1999

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common stock, par value $0.001 per share

     

    KRRO

     

    The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On August 12, 2025, Korro Bio, Inc., or Korro, issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    No.

     

    Description

     

     

     

    99.1

     

    Press Release issued by Korro Bio, Inc., dated August 12, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    KORRO BIO, INC.

     

     

    Date: August 12, 2025

    By:

    /s/ Ram Aiyar

     

     

     

     

     

    Name: Ram Aiyar

     

     

    Title: President and Chief Executive Officer

     

     


    Get the next $KRRO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    4/29/2025$74.00Overweight
    Cantor Fitzgerald
    4/16/2025$25.00Buy
    Chardan Capital Markets
    1/10/2025$155.00Outperform
    Oppenheimer
    10/21/2024$153.00Strong Buy
    Raymond James
    8/14/2024$180.00Outperform
    William Blair
    3/28/2024$100.00 → $115.00Buy
    H.C. Wainwright
    2/27/2024$120.00Outperform
    BMO Capital Markets
    12/4/2023$100.00Buy
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

    — Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro's rare metabolic disorder program will be announced by end of 2025 — Ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities  CAMBRIDGE, Mass., Aug. 12, 2025

    8/12/25 7:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

    CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). "The EMA orphan drug designation for KRRO-110 is a significant milestone for Korro and highlights an urgent need to bring innovative solutions to people with AATD seeking new, disease-modify

    7/21/25 8:00:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc

    5/14/25 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:19 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:26 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    4/24/24 5:00:16 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Korro Bio with a new price target

    Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00

    4/29/25 8:10:45 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Korro Bio with a new price target

    Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00

    4/16/25 9:07:30 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Korro Bio with a new price target

    Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00

    1/10/25 8:59:40 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.

    SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    8/14/25 4:53:12 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.

    SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    8/13/25 3:50:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Korro Bio Inc.

    10-Q - Korro Bio, Inc. (0001703647) (Filer)

    8/12/25 7:10:48 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Behbahani Ali

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/12/25 4:40:18 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Meyers Rachel

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/12/25 4:32:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bermingham Nessan

    4 - Korro Bio, Inc. (0001703647) (Issuer)

    6/12/25 4:29:03 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    View All

    Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    4/1/25 7:30:00 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    12/10/24 8:00:00 AM ET
    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    11/12/24 4:05:00 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 7:54:42 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 3:04:22 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

    SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

    11/14/24 12:21:08 PM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care